Phreesia (NYSE:PHR) Given New $14.00 Price Target at Needham & Company LLC

Phreesia (NYSE:PHR) had its price target reduced by Needham & Company LLC from $35.00 to $14.00 in a research report report published on Tuesday, MarketBeat.com reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently commented on PHR. Mizuho decreased their target price on shares of Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. JPMorgan Chase & Co. cut their price target on shares of Phreesia from $29.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 20th. Zacks Research downgraded Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Citigroup decreased their price objective on Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a report on Friday, January 9th. Finally, Barclays lowered their price objective on Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, December 16th. Thirteen investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.00.

Phreesia Stock Performance

Shares of Phreesia stock opened at $8.33 on Tuesday. The company has a market capitalization of $502.28 million, a PE ratio of 277.70 and a beta of 0.67. The company has a 50-day simple moving average of $12.36 and a two-hundred day simple moving average of $17.57. Phreesia has a one year low of $7.77 and a one year high of $32.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.33%. The firm had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. Research analysts expect that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Activity at Phreesia

In other Phreesia news, insider Evan Roberts sold 6,268 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total transaction of $102,544.48. Following the transaction, the insider owned 826,554 shares in the company, valued at approximately $13,522,423.44. This represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Balaji Gandhi sold 3,829 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total transaction of $43,114.54. Following the transaction, the chief financial officer owned 146,740 shares in the company, valued at $1,652,292.40. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 70,358 shares of company stock worth $1,123,569 in the last 90 days. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Phreesia

Several hedge funds have recently made changes to their positions in PHR. Granahan Investment Management LLC raised its stake in Phreesia by 73.8% in the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after acquiring an additional 1,018,987 shares during the last quarter. Prosight Management LP purchased a new stake in Phreesia during the 4th quarter valued at about $16,533,000. Millennium Management LLC increased its holdings in shares of Phreesia by 730.7% in the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock valued at $25,028,000 after purchasing an additional 936,033 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Phreesia in the fourth quarter valued at about $15,213,000. Finally, Greenhouse Funds LLLP raised its stake in shares of Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after purchasing an additional 557,265 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.